At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 152 enrolled
Drug / intervention
Omeprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
In Brief
A Phase 4 clinical trial evaluating Omeprazole and LINX Reflux Management System for GERD Gastroesophageal Reflux Disease. Completed, enrolled 152 participants across 21 sites.
Detailed Summary
This study compares mechanical sphincter augmentation (LINX Reflux Management System) to double-dose proton pump inhibitors (PPIs) for the management of reflux symptoms related to gastroesophageal reflux disease (GERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGERD Gastroesophageal Reflux Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJul 2015
Primary CompletionOct 2017
Study CompletionAug 2018
TodayJul 2026
First PostedJul 22, 2015
Enrollment StartJun 1, 2015
Primary CompletionOct 1, 2017
Study CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.9 years ago
Interventions
Omeprazoledrug
LINX Reflux Management Systemdevice